21 research outputs found
A Second Look or, Not to Mention the Occasional Capsizing of a Windsurfer
Of
all of the epithelial ovarian cancers (EOC), clear cell adenocarcinoma
(CCA) has the worst clinical prognosis. Furthermore, the conventional
EOC biomarker CA125 is more often negative in CCA than in other subtypes
of EOC. This study sought to discover a new diagnostic biomarker that
would allow more reliable detection of CCA. Using mass spectrometry,
we compared proteins in conditioned media from cell lines derived
from CCA and other types of EOC. We identified 30 extracellular or
released proteins specifically present in CCA-derived cell lines.
Bioinformatics analyses identified a serine protease inhibitor, tissue
factor pathway inhibitor 2 (TFPI2), as a potential biomarker for CCA.
Real time RT-PCR and Western blot analyses revealed that TFPI2 was
exclusively expressed in CCA-derived cell lines and tissues. For clinical
validation, we measured levels of TFPI2 and CA125 in a set of sera
from 30 healthy women, 30 patients with endometriosis, and 50 patients
with CCA, using an automated enzyme-linked immunosorbent assay systems.
Serum levels of TFPI2 were significantly elevated in CCA patients,
even those with normal CA125 levels. In terms of area under the receiver
operating characteristic curve (AUC), TFPI2 was superior to CA125
in discriminating CCA patients from healthy women (AUC 0.97 for TFPI2
versus AUC 0.80 for CA125), or from patients with endometriosis (AUC
0.93 for TFPI2 versus 0.80 for CA125). This is the first evidence
for TFPI2 as a serum biomarker of CCA. We propose that this biomarker
may be useful for detection of CCA and for monitoring the transformation
from endometriosis into CCA
Adjusted odds ratios for adverse perinatal outcomes during the second pregnancy in relation to interpregnancy BMI changes.
Adjusted odds ratios for adverse perinatal outcomes during the second pregnancy in relation to interpregnancy BMI changes.</p
Maternal characteristics and perinatal outcomes at the first and second pregnancy.
Maternal characteristics and perinatal outcomes at the first and second pregnancy.</p
Participants classified by interpregnancy BMI changes and maternal characteristics and perinatal outcomes at first pregnancy.
Participants classified by interpregnancy BMI changes and maternal characteristics and perinatal outcomes at first pregnancy.</p
Flowchart in the selection of study participants.
Previous studies have shown that interpregnancy weight fluctuations impact perinatal outcomes. In order to examine this in Japanese women, we analyzed the data of 2,861 women in their first and second pregnancies who delivered singletons between 2000 and 2022. We compared the second pregnancy perinatal outcomes of women whose interpregnancy body mass index (BMI) change was -1 to 1 unit with those of women whose BMI change was 2 before their first pregnancy were associated with a remarkable risk reduction of developing gestational diabetes mellitus (aOR, 0.33; 95% CI, 0.12–0.88). Weight gain during interpregnancy period was related to an increased risk of gestational diabetes mellitus and delivery of a large-for-gestational-age neonate, whereas weight loss was related to a decreased risk of developing gestational diabetes mellitus. These results indicate the importance of interpregnancy weight control as part of preconception care; therefore, women considering additional pregnancies should be educated on the importance of maintaining a healthy weight.</div
Adjusted odds ratios for adverse perinatal outcomes during the second pregnancy in relation to interpregnancy BMI changes between the first and second pregnancy stratified by prepregnancy BMI at the first pregnancy.
Adjusted odds ratios for adverse perinatal outcomes during the second pregnancy in relation to interpregnancy BMI changes between the first and second pregnancy stratified by prepregnancy BMI at the first pregnancy.</p
STROBE statement—checklist of items that should be included in reports of observational studies.
STROBE statement—checklist of items that should be included in reports of observational studies.</p
L'Éclaireur du dimanche et "La Vie pratique, Courrier des étrangers"
09 septembre 19231923/09/09 (N148,A4)-1923/09/09.Appartient à l’ensemble documentaire : PACA
Additional file 3: Figure S2. of Human liver organoids generated with single donor-derived multiple cells rescue mice from acute liver failure
Showing characterization of hiPSCs reprogrammed from human UC-ECs. A Flow cytometry analysis of UC-ECs and EC-iPSCs expressing TRA-1-60, SSEA4, and CD31. B Expression of pluripotency-related genes (OCT4, NANOG, LIN28A, SOX2, and KLF4) and EC-related genes (CD31, TIE1, ERG, and vWF) in UC-ECs (n = 4) and EC-hiPSCs (n = 4), as determined by qPCR (n = 4). (PDF 152 kb
Secretome-Based Identification of TFPI2, A Novel Serum Biomarker for Detection of Ovarian Clear Cell Adenocarcinoma
Of
all of the epithelial ovarian cancers (EOC), clear cell adenocarcinoma
(CCA) has the worst clinical prognosis. Furthermore, the conventional
EOC biomarker CA125 is more often negative in CCA than in other subtypes
of EOC. This study sought to discover a new diagnostic biomarker that
would allow more reliable detection of CCA. Using mass spectrometry,
we compared proteins in conditioned media from cell lines derived
from CCA and other types of EOC. We identified 30 extracellular or
released proteins specifically present in CCA-derived cell lines.
Bioinformatics analyses identified a serine protease inhibitor, tissue
factor pathway inhibitor 2 (TFPI2), as a potential biomarker for CCA.
Real time RT-PCR and Western blot analyses revealed that TFPI2 was
exclusively expressed in CCA-derived cell lines and tissues. For clinical
validation, we measured levels of TFPI2 and CA125 in a set of sera
from 30 healthy women, 30 patients with endometriosis, and 50 patients
with CCA, using an automated enzyme-linked immunosorbent assay systems.
Serum levels of TFPI2 were significantly elevated in CCA patients,
even those with normal CA125 levels. In terms of area under the receiver
operating characteristic curve (AUC), TFPI2 was superior to CA125
in discriminating CCA patients from healthy women (AUC 0.97 for TFPI2
versus AUC 0.80 for CA125), or from patients with endometriosis (AUC
0.93 for TFPI2 versus 0.80 for CA125). This is the first evidence
for TFPI2 as a serum biomarker of CCA. We propose that this biomarker
may be useful for detection of CCA and for monitoring the transformation
from endometriosis into CCA